Medtronic: Undervalued, And The Tailwinds Are Just Getting Started

I initiate coverage on Medtronic, highlighting its status as a leading medtech name with premium margins. MDT offers an attractive diversification opportunity, combining consistent performance with accelerated revenue growth. The stock trades at undervalued levels, supporting a long-term bullish thesis and a defensive investment approach. I assign a "Buy" rating to MDT while acknowledging risks that could challenge the bull case. I've decided to initiate coverage on Medtronic (MDT). I find the company to be an interesting diversification opportunity. It remains a leading name in the medtech space and fundamentally operates with premium margins. And, if that wasn't enough, MDT also trades at an undervalued level.